30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

Saved in:

Bibliographic Details
Main Authors:	Enrique M. Ocio, Aurore Perrot, Philippe Moreau, Maria‐Victoria Mateos, Sara Bringhen, Joaquín Martínez‐López, Lionel Karlin, Song‐Yau Wang, Corina Oprea, Yi Li, Ercem Kodas, Jesus San‐Miguel
Format:	Article
Language:	English
Published:	Wiley 2024-11-01
Series:	HemaSphere
Online Access:	https://doi.org/10.1002/hem3.70041
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
by: Salomon Manier, et al.
Published: (2025-03-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey
by: Nuria Sánchez Avello, et al.
Published: (2025-06-01)

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials
by: Muhammed Favas Karimbanathottathil, et al.
Published: (2024-12-01)

FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q+
by: Jiro Kikuchi, et al.
Published: (2025-07-01)

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020
by: Laure Vincent, et al.
Published: (2025-03-01)

Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data
by: Antoine Pitoy, et al.
Published: (2024-12-01)

A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab
by: Daniel Thomas Jones, et al.
Published: (2025-03-01)

Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report
by: Takanori Yoshioka, et al.
Published: (2025-01-01)

Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
by: Enrica Antonia Martino, et al.
Published: (2025-03-01)

A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
by: Sargam Rachit Vohra, et al.
Published: (2025-07-01)

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
by: Hongjie Wang, et al.
Published: (2024-12-01)

Predicting survival of persons with newly-diagnosed multiple myeloma
by: Limei Zhang, et al.
Published: (2025-08-01)

Exciting New Data in Newly Diagnosed Multiple Myeloma
by: Kaveh Samii
Published: (2022-10-01)

Outcomes for unselected, newly diagnosed multiple myeloma patients
by: Jonathan T. Moore, et al.
Published: (2025-06-01)

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
by: Theo Leitner, et al.
Published: (2024-12-01)

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
by: Grace M. Ferri, et al.
Published: (2025-01-01)

Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes
by: Maria Teresa Petrucci, et al.
Published: (2024-12-01)

Prognostic value of peripheral eosinophil counts in patients with newly diagnosed multiple myeloma
by: Xu Chen, et al.
Published: (2025-05-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
by: Roberto Ria, et al.
Published: (2012-01-01)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
by: Wen‐Ying Lin, et al.
Published: (2023-02-01)

IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma
by: Shuaishuai Xu, et al.
Published: (2024-12-01)

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01)

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: Francesca Fazio, et al.
Published: (2023-08-01)

Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
by: Florent Malard, et al.
Published: (2024-12-01)

Keeping an Eye on Bisphosphonate Therapy in Myeloma: A Case Report of Ocular Inflammation Postzoledronic Acid Infusion
by: Rehman Faryal, et al.
Published: (2021-01-01)

Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma
by: Eider F. Moreno-Cortes, et al.
Published: (2025-08-01)

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
by: Matthew J. Pianko, et al.
Published: (2025-12-01)

A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs
by: Ye Li, et al.
Published: (2024-10-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
by: Yuxin Liu, et al.
Published: (2024-10-01)

Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients
by: Xu Si, et al.
Published: (2025-05-01)

15 Minutes: Belarus!
by: Aleh Dashkevich, et al.
Published: (2014-06-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Tregs at Diagnosis as a Potential Biomarker for Predicting High‐Risk Functionality in Newly Diagnosed Multiple Myeloma
by: Qiaolin Zhou, et al.
Published: (2025-06-01)

Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial
by: Lisa B. Leypoldt, et al.
Published: (2025-07-01)

Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
by: Deepesh P. Lad
Published: (2024-04-01)

Clinical Characteristics and Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients in China
by: Geng C, et al.
Published: (2025-05-01)

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
by: E. Bridget Kim, et al.
Published: (2025-07-01)